Intestinal MDR transport proteins and P-450 enzymes as barriers to oral drug delivery

Journal of Controlled Release

Volumn 62, Issue 1-2, 1999, Pages 25-31

  Benet, Leslie Z ^a   Izumi, Takashi ^a,b   Zhang, Yuanchao ^a   Silverman, Jeffrey A ^c   Wacher, Vincent J ^c  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b DAIICHI SANKYO CO   (Japan)

^c AvMax Inc   (United States)

Author keywords

Countertransport; Cyclosporine; Cytochrome P450 3A; Gut metabolism; P glycoprotein

Indexed keywords

CYCLOSPORIN; CYTOCHROME P450; CYTOCHROME P450 3A4; GLYCOPROTEIN P; INDINAVIR; KETOCONAZOLE; MIDAZOLAM; RIFABUTIN; RIFAMPICIN; SAQUINAVIR; TACROLIMUS; TOCOFERSOLAN; UNCLASSIFIED DRUG;

ARTICLE; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG DELIVERY SYSTEM; DRUG METABOLISM; INTESTINE CELL; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL;

ADMINISTRATION, ORAL; ANIMALS; BIOLOGICAL AVAILABILITY; BIOLOGICAL TRANSPORT; CARRIER PROTEINS; CELL LINE; CYSTEINE PROTEINASE INHIBITORS; CYTOCHROME P-450 ENZYME SYSTEM; DRUG DELIVERY SYSTEMS; INTESTINAL ABSORPTION; LIVER; MODELS, BIOLOGICAL; P-GLYCOPROTEIN; RATS; TRANSFECTION;

EID: 0032825148     PISSN: 01683659     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0168-3659(99)00034-6     Document Type: Article

References (32)

1. Benet L.Z., Wu C.-Y., Hebert M.F., Wacher V.J. Intestinal drug metabolism and antitransport processes: A potential paradigm shift in oral drug delivery. J. Control. Release. 39:1996;139-143.
2. Rowland M., Tozer T.N. Clinical Pharmacokinetics: Concepts and Applications. 3rd Edn :1995;Williams and Wilkins, Baltimore.
3. Wacher V.J., Wu C.Y., Benet L.Z. Overlapping substrate specificities and tissue distribution of cytochrome P-450 3A and P-glycoprotein have implications for drug delivery and activity in cancer chemotherapy. Mol. Carcinog. 13:1995;129-134.
4. Gomez D.Y., Wacher V.J., Tomlanovich S.J., Hebert M.F., Benet L.Z. The effects of ketoconazole on the intestinal metabolism and bioavailability of cyclosporine. Clin. Pharmacol. Ther. 58:1995;15-19.
5. Floren L.C., Bekersky I., Benet L.Z., Mekki Q., Dressler D., Lee J.W., Roberts J.P., Hebert M.F. Tacrolimus oral bioavailability doubles with coadministration of ketoconazole. Clin. Pharmacol. Ther. 62:1997;41-49.
6. Hebert M.F., Roberts J.P., Prueksaritanont T., Benet L.Z. Bioavailability of cyclosporine with concomitant rifampin administration is markedly less than predicted by hepatic enzyme induction. Clin. Pharmacol. Ther. 52:1992;453-455.
7. Lown K.S., Mayo R.R., Leichtman A.B., Hsiao H., Turgeon D.K., Schmiedlin-Ren P., Brown M.B., Guo W., Rossi S.J., Benet L.Z., Watkins P.B. Role of intestinal P-glycoprotein (mdr1) in interpatient variation in the oral bioavailability of cyclosporine. Clin. Pharmacol. Ther. 62:1997;248-260.
8. van Asperen J., van Tellingen O., Sparreboom A., Schinkel A.H., Borst P., Nooijen W.J., Beijnen J.H. Enhanced oral bioavailability of palitaxel in mice treated with the P-glycoprotein blocker SDZ PSC 833. Br. J. Cancer. 76:1997;1181-1183.
9. Salphati L., Benet L.Z. Effects of ketoconazole on digoxin absorption and disposition in rat. Pharmacology. 56:1998;308-313.
10. Kim R.B., Fromm M.F., Wandel C., Leake B., Wood A.J.J., Roden D.M., Wilkinson G.R. The drug transporter P-glycoprotein limits oral absorption and brain entry of HIV-1 protease inhibitors. J. Clin. Invest. 101:1998;289-294.
11. Kim A.E., Dintaman J.M., Waddell D.S., Silverman J.A. Saquinavir, an HIV protease inhibitor, is transported by P-glycoprotein. J. Pharmacol. Exp. Ther. 286:1998;1439-1445.
12. Zhang Y., Guo X., Lin E.T., Benet L.Z. Overlapping substrate specificities of cytochrome P450 3A and P-glycoprotein for a novel cysteine protease inhibitor. Drug Metab. Dispos. 26:1998;360-366.
13. Shimada T., Yamazaki T.H., Mimura M., Inui Y., Guengerich F.P. Interindividual variations in human liver cytochrome P-450 enzymes involved in the oxidation of drugs, carcinogens and toxic chemicals: studies with liver microsomes of 30 Japanese and 30 caucasians. J. Pharmacol. Exp. Ther. 270:1994;414-423.
14. Watkins P.B., Wrighton S.A., Schuetz E.G., Molowa D.T., Guzelian P.S. Identification of glucocorticoid-inducible cytochromes P450 in the intestinal mucosa of rats and man. J. Clin. Invest. 80:1987;1029-1036.
15. Benet L.Z., Kroetz D.L., Sheiner L.B. Pharmacokinetics: The dynamics of drug absorption, distribution, and elimination. Hardman J.G., Limbird L.E., Molinoff P.B., Ruddon R.W., Goodman A.G. Goodman and Gilman's The Pharmacologic Basis of Therapeutics. 9th Edn :1996;3-27 McGraw-Hill, New York.
16. Wacher V.J., Silverman J.A., Zhang Y., Benet L.Z. Role of P-glycoprotein and cytochrome P450 3A in limiting oral absorption of peptides and peptidomimetics. J. Pharm. Sci. 87:1998;1322-1330.
17. Paine M.F., Khalighi M., Fisher J.M., Shen D.D., Kunze K.L., Marsh C.L., Perkins J.D., Thummel K.E. Characterization of interintestinal and intraintestinal variations in human CYP3A-dependent metabolism. J. Pharmacol. Exp. Ther. 283:1997;1552-1562.
18. Lown K.S., Ghosh M., Watkins P.B. Sequences of intestinal and hepatic and cytochrome P450 3A4 cDNAs are identical. Drug Metab. Dispos. 26:1998;185-187.
19. Lown K.S., Kolars J.C., Thummel K.E., Barnett J.L., Kunze K.L., Wrighton S.A., Watkins P.B. Interpatient heterogeneity in expression of CYP3A4 and CYP3A5 in small bowel. Lack of prediction by erythromycin breath test. Drug Metab. Dispos. 22:1994;947-955.
20. Gottesman M.M., Pastan I. Biochemistry of multidrug resistance mediated by the multidrug transporter. Annu. Rev. Biochem. 62:1993;385-427.
21. Fojo A.T., Ueda K., Slamon D.J., Poplack D.G., Gottesman M.M., Pastan I. Expression of a multidrug-resistance gene in human tumors and tissues. Proc. Natl. Acad. Sci. USA. 84:1987;265-269.
22. Lown K.S., Bailey D.G., Fontana R.J., Janardan S.K., Adair C.H., Fortlage L.A., Brown M.B., Guo W., Watkins P.B. Grapefruit juice increases felodipine oral availability in humans by decreasing intestinal CYP3A protein expression. J. Clin. Invest. 99:1997;2545-2553.
23. Chang T., Benet L.Z., Hebert M.F. Effect of water-soluble vitamin E on cyclosporine pharmacokinetics in healthy volunteers. Clin. Pharmacol. Ther. 59:1996;297-303.
24. Palmer J.T., Rasnick D., Klaus J.L., Bromme D. Vinyl sulfones as mechanism-based cysteine protease inhibitors. J. Med. Chem. 38:1995;3193-3196.
25. Zhang Y., Hsieh Y., Izumi T., Lin E.T., Benet L.Z. Effects of ketoconazole on the intestinal metabolism, transport and oral bioavailability of K02, a novel vinylsulfone peptidomimetic cysteine protease inhibitor and a P450 3A, P-glycoprotein dual substrate, in male Sprague-Dawley rats. J. Pharmacol. Exp. Ther. 287:1998;246-252.
26. Wu C.-Y., Benet L.Z., Hebert M.F., Gupta S.K., Rowland M., Gomez D.Y., Wacher V.J. Differentiation of absorption and first-pass gut and hepatic metabolism in humans: Studies with cyclosporine. Clin. Pharmacol. Ther. 58:1995;492-497.
27. Gupta S.K., Bakran A., Johnson R.W.G., Rowland M. Cyclosporine-erythromycin interaction in renal transplant patients. Br. J. Clin. Pharmacol. 27:1989;475-481.
28. Izumi T., Benet L.Z. A new model for predicting in vivo intestinal metabolism from in vitro data. DDPT Abstracts of the Conference on Challenges for Drug Delivery and Pharmaceutical Technology, Tokyo, Japan, June 9-11, 1998 :1998;83 Business Center for Academic Societies, Tokyo. ISBN 4-930813-85-9.
29. Thummel K.E., O'Shea D., Paine M.F., Shen D.D., Kunze K.L., Perkins J.D., Wilkinson G.R. Oral first-pass elimination of midazolam involves both gastrointestinal and hepatic CYP3A-mediated metabolism. Clin. Pharmacol. Ther. 59:1996;491-502.
30. Chiba M., Hensleigh M., Lin J.H. Hepatic and intestinal metabolism of indinavir, an HIV protease inhibitor, in rat and human microsomes. Major role of CYP3A. Biochem. Pharmacol. 53:1997;1187-1195.
31. Fitzsimmons M.E., Collins J.M. Selective biotransformation of the human immunodeficiency virus protease inhibitor saquinavir by human small-intestinal cytochrome P4503A4. Potential contribution to high first-pass metabolism. Drug Metab. Dispos. 25:1997;256-266.
32. Iatsimirskaia E., Tulebaev S., Storozhuk E., Utkin I., Smith D., Gerber N., Koudriakoa T. Metabolism of rifabutin in human enterocyte and liver microsomes: kinetic parameters, identification of enzyme systems, and drug interactions with macrolides and antifungal agents. Clin. Pharmacol. Ther. 61:1997;554-562.